D.A. Davidson & CO. Makes New $417,000 Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

D.A. Davidson & CO. bought a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,244 shares of the company's stock, valued at approximately $417,000.

Other large investors have also recently bought and sold shares of the company. Pacer Advisors Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock valued at $50,139,000 after purchasing an additional 1,347,775 shares during the period. Boston Trust Walden Corp increased its position in shares of Amphastar Pharmaceuticals by 81.4% in the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after buying an additional 439,281 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Amphastar Pharmaceuticals by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock valued at $44,674,000 after buying an additional 14,015 shares in the last quarter. Portolan Capital Management LLC increased its holdings in Amphastar Pharmaceuticals by 201.1% during the 3rd quarter. Portolan Capital Management LLC now owns 327,764 shares of the company's stock worth $15,906,000 after purchasing an additional 218,901 shares in the last quarter. Finally, Nordea Investment Management AB increased its holdings in Amphastar Pharmaceuticals by 4.8% during the 4th quarter. Nordea Investment Management AB now owns 279,714 shares of the company's stock worth $10,386,000 after purchasing an additional 12,851 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Remove Ads

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH traded down $3.06 during mid-day trading on Friday, hitting $28.43. The stock had a trading volume of 1,792,655 shares, compared to its average volume of 569,799. Amphastar Pharmaceuticals, Inc. has a twelve month low of $27.82 and a twelve month high of $53.96. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of 9.48, a PEG ratio of 2.19 and a beta of 0.81. The company's 50 day simple moving average is $34.74 and its 200 day simple moving average is $42.57. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AMPH. Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 price objective for the company. StockNews.com cut Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Finally, Piper Sandler cut Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $66.00 to $36.00 in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $50.33.

Insider Activity at Amphastar Pharmaceuticals

In related news, Director Richard K. Prins sold 10,000 shares of the firm's stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the sale, the director now directly owns 30,471 shares in the company, valued at approximately $1,333,715.67. This trade represents a 24.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Rong Zhou sold 7,000 shares of the firm's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the sale, the executive vice president now owns 118,469 shares of the company's stock, valued at $5,262,392.98. This trade represents a 5.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 27.10% of the stock is currently owned by company insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.